InvestSMART

Bioxyne Limited (ASX:BXN)

ALERT: Price-sensitive ASX Announcement for BXN
Current share price for BXN : $0.930 0.86 (1,228.57%)+
Announcement
Release
11 May 2026 8:24AM
Price at Release
$0.070
Full Release
download
Summary
Bioxyne Limited, through its subsidiary Breathe Life Sciences, has expanded its supply agreement with Remidose LATAM to include the supply of Dr Watson® cannabis flower products to Costa Rica. This expanded agreement marks the first international supply of medicinal cannabis flower into Costa Rica's regulated market, reflecting strong early-stage demand. The first shipment, valued over $500,000, is expected before 30 June 2026. This agreement not only strengthens Bioxyne's presence in the LATAM region but also aligns with its strategic plan to grow its GMP-certified manufacturing and supply platform internationally, with a focus on Europe and LATAM as key growth regions.
Key Points
  • Bioxyne expands supply agreement with Remidose LATAM.
  • First international supply of medicinal cannabis flower to Costa Rica.
  • Initial shipment valued over $500,000 by 30 June 2026.
  • Supports Bioxyne's strategic growth in LATAM and Europe.
  • Bioxyne entering early-stage regulated market with growth potential.
  • Dr Watson® brand introduced into Costa Rican market.
  • First-mover advantage in LATAM cannabis market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.